Pharmaceutical company GlaxoSmithKline is expecting sales of its pandemic flu vaccines to be below expectations as Germany and other European governments cut their orders.
Recently GSK reported last year’s sales on flu vaccines reached £835 million, meaning combined sales for 2009 and 2010 are well below the £2 million forecast by the company.
Following a deal by Germany to reduce orders for swine flu vaccines by 30%, markets in France and the UK are predicted to do the same.
The fall in demand has come as the public have voiced concerns over its side effects and the spread of the pandemic has slowed down across Europe and North America.
GSK will release its full-year results next month and other manufacturers, such as Sanofi-Aventis and Novartis are also expected to see a fall in sales.
Copyright Press Association 2010